新型聚乙二醇干扰素治疗慢性病毒性肝炎

StephenW

新型聚乙二醇干扰素治疗慢性病毒性肝炎
黄一文 1 2 3 , Albert Qin 4 , Chan-Yen Tsai 4 , Pei-Jer Chen 5 6
隶属关系
隶属关系

    1
    台北医科大学附属医院内科及临床研究中心肠胃肝病科，台北 110，台湾。
    2
    台北医科大学医学院医学院内科消化内科和肝内科，台北110，台湾。
    3
    台湾大学医学院医学院，台北 100。
    4
    PharmaEssentia Corporation，台北 115，台湾。
    5
    台湾大学医学院临床医学研究所，台北 100。
    6
    台湾大学附属医院肝炎研究中心，台北 100。

    PMID：35746606 DOI：10.3390/v14061128

抽象的

Ropeginterferon alfa-2b 是一种新型单聚乙二醇化超长效干扰素，正在开发用于治疗骨髓增生性肿瘤 (MPN) 和慢性病毒性肝炎。与具有多种异构体且每周给药的常规聚乙二醇化干扰素产品相比，它具有良好的药代动力学特征和较低频率的给药方案，即每两到四周一次。它被批准用于真性红细胞增多症（一种 MPN）的长期治疗，并已被纳入该适应症的 NCCN 临床实践指南。在多项临床研究中，Ropeginterferon alfa-2b 已证明有效，并显示出治疗慢性病毒性肝炎的良好安全性。在本文中，我们回顾了其药代动力学和现有临床数据，并建议每两周给药一次的ropeginterferon alfa-2b可以作为慢性病毒性肝炎（包括慢性乙型、丙型和丁型肝炎）患者的新治疗选择。

关键词：慢性乙型肝炎；慢性丙型肝炎；慢性丁型肝炎；临床试验;干扰素；绳索干扰素α-2b。
出版物类型

    审查

StephenW

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis
Yi-Wen Huang  1   2   3 , Albert Qin  4 , Chan-Yen Tsai  4 , Pei-Jer Chen  5   6
Affiliations
Affiliations

    1
    Division of Gastroenterology and Hepatology, Department of Internal Medicine and Clinical Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan.
    2
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
    3
    School of Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan.
    4
    PharmaEssentia Corporation, Taipei 115, Taiwan.
    5
    Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan.
    6
    Hepatitis Research Center, National Taiwan University Hospital, Taipei 100, Taiwan.

    PMID: 35746606 DOI: 10.3390/v14061128

Abstract

Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis. It has a favorable pharmacokinetic profile and less frequent dosing schedule, i.e., once every two to four weeks, compared to conventional pegylated interferon products, which have multiple isomers and are administered weekly. It was approved for the long-term treatment of polycythemia vera, an MPN, and has been included in the NCCN clinical practice guidelines for this indication. Ropeginterferon alfa-2b has demonstrated efficacy and showed a favorable safety profile for the treatment of chronic viral hepatitis in several clinical studies. In this article, we review its pharmacokinetics and available clinical data and suggest that ropeginterferon alfa-2b administered once every two weeks can serve as a new treatment option for patients with chronic viral hepatitis, including chronic hepatitis B, C, and D.

Keywords: chronic hepatitis B; chronic hepatitis C; chronic hepatitis D; clinical trial; interferon; ropeginterferon alfa-2b.
Publication types

    Review

StephenW

https://www.mdpi.com/1999-4915/14/6/1128/pdf?version=1653441521

lancas

如果效果可以，2周一次给药还是不错的~